Clinical effectiveness and side effects of different treatment methods for lung cancer

Not Applicable

Completed

• Conditions: EGFR mutation-positive advanced lung adenocarcinoma; Cancer

• Registration Number: ISRCTN14796973
• Lead Sponsor: Fujian Provincial Hospital

Brief Summary

2022 Results article in https://doi.org/10.1177/1721727X22114544 (added 20/04/2023)

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Completion: 2020-10-01
• Study Start: 2022-10-22
• Last Update Posted: 1 May 2023

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 103

Inclusion Criteria

1. Initial treatment of lung adenocarcinoma confirmed by pathology or cytology
2. Classic mutation of EGFR gene
3. Minimum life expectancy 3 months
4. Patients with clinical stage III ~ IV were considered as advanced lung cancer after comprehensive evaluation of imaging, medical history and examination at the same time, and were excluded from other malignant tumors

Exclusion Criteria

Does not meet the inclusion criteria

Study & Design

• Study Type: Observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
1. Long-term efficacy: tumor progression-free survival (PFS) and survival calculated from enrollment to 1-year and 3-year follow-up<br>2. Adverse effects: the occurrence and severity of adverse events, including acute central nervous system adverse reactions, acute radiation pneumonia, vomiting, nausea, rash, diarrhea, liver function damage, and bone marrow suppression, using the commonly used term evaluation criterion (CTCAE4.0) of the National Cancer Center of Adverse Events and the tumor radiotherapy group (RTOG) classification standard. Calculated at 1-year and 3-year follow-up